{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Pain Management Survey 2
Please help us understand some practical aspects of cancer pain management & its treatment in your practice. We would appreciate if you can take few moments to give your valuable comments in questionnaire below.
  1. Who are right group of patients for below mentioned molecules? *
  2. In which of the cancer patients you see oral morphine intake as a challenge? *

    3. Would you prefer to use buprenorphine transdermal patches in these patients? *

  3. Buprenorphine transdermal patches are available in 5, 10 and 20 mcg strengths. As per the recommendation, dosage can go up to 40 mcg (2 patches of 20 mcg of Prosia patch). Do you use dose > 20 mcg? *

  4. What is the approximate percentage-wise split of patients whom you prescribe Buprenorphine in following dosage range? *
    5. 10-20 mcg/hr
    %
    20-30 mcg/hr
    %
    30-40 mcg/hr
    %
    > 40 mcg/hr
    %
  5. While using morphine, approximately what % of your patients suffer following side effects? *
    6. Moderate to severe constipation
    %
    Dizziness
    %
    Strong withdrawal Symptoms
    %
    Respiratory depression
    %
    %
  6. Do you feel your patients face some challenges in procuring opioid analgesics such as morphine tablets or fentanyl transdermal patches as it comes under NDPS act? *

  7. Is Morphine available in your hospital 24-7? *

  8. Is Fentanyl transdermal patches available in your hospital 24*7? *

  9. While managing moderate to severe cancer pain, do you use equi-analgesic dose conversion after morphine stabilization? *

  10. In your clinical practice, approximately what percentage of cancer patients do you use following strengths of fentanyl patch on the basis of equi-analgesic dose conversion? *
    11. 12.5 mcg/hr
    %
    25 mcg/hr
    %
    50 mcg/hr
    %
    %
  11. While using fentanyl, approximately what % of your patients suffer from following side effects? *
    12. Moderate to severe constipation
    %
    Dizziness
    %
    Strong withdrawal Symptoms
    %
    Respiratory depression
    %
    %
  12. While using complete µ (Mu) agonist (Morphine or Fentanyl), approximately what % of your patients develop drug tolerance? *
    13. %
  13. Among following molecules, what percentage of your patients need dose escalations more frequently due to drug tolerance? *
    14. Name of molecule Percentage of patients needing dose escalations
    Morphine
    %
    Fentanyl
    %
    Buprenorphine
    %
  14. As per your opinion, what are 2-3 reasons of preferring Buprenorphine patches over other strong opioid formulations? *
    15. 1
    2
    3
  15. Do you feel Buprenorphine being partial agonist of µ agonist is less efficacious than complete µ agonist such as morphine or fentanyl? *